# US 2013/0295564 A1 · Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0295564 A1
- Document ID: US20130295564A1
- Status: Published application
- Kind: A1
- Application number: 13/791,466
- Filed: 2013-03-08
- Published: 2013-11-07
- Earliest claimed: 2008-09-16
- Assignees: Sequenom Center for Molecular Medicine; Sequenom, Inc.
- Inventors: Mathias EHRICH; Anders Olof Herman NYGREN; Tyler Jacob JENSEN
- Web page: https://patentgrep.com/patent/US20130295564A1

## CPC

- C12Q 1/6869: Methods for sequencing
- C12Q 1/6804: Nucleic acid analysis using immunogens (immunoassay G01N33/53)
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6809: Methods for determination or identification of nucleic acids involving differential detection
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/6888: for detection or identification of organisms
- C12Q 1/6879: for sex determination
- C12Q 2600/154: Methylation markers
- C12Q 2600/16: Primer sets for multiplex assays
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Provided are compositions and processes that utilize genomic regions that are differentially methylated between a mother and her fetus to separate, isolate or enrich fetal nucleic acid from a maternal sample. The compositions and processes described herein are particularly useful for non-invasive prenatal diagnostics, including the detection of chromosomal aneuploidies.

## Claims

### Claim 1

A method for determining the amount of fetal nucleic acid in a sample comprising:
a) contacting nucleic acid from a pregnant female, which nucleic acid comprises fetal nucleic acid and maternal nucleic acid, the combination of the fetal nucleic acid and the maternal nucleic acid comprising total nucleic acid in the sample, with a methylation sensitive restriction enzyme that specifically digests the maternal nucleic acid at a plurality of loci, wherein the plurality of loci comprises:
i) loci that are hypermethylated in fetal nucleic acid; and
ii) one or more loci selected from loci of SEQ ID NOs:90-163, 176, 179, 180, 184, 188, 189, 190, 191, 193, 195, 198, 199, 200, 201, 202, 203, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 221, 223, 225, 226, 231, 232, 233, 235, 239, 241, 257, 258, 259, and 261, thereby enriching the fetal nucleic acid;
b) determining the amount of fetal nucleic acid in the sample.

### Claim 2 (depends on 1)

The method of claim 1, comprising determining the amount of total nucleic acid present in the sample.

### Claim 3 (depends on 2)

The method of claim 2, wherein determining the amount of fetal nucleic acid in the sample comprises comparing the amount of fetal nucleic acid in (b) to the total amount of nucleic acid.

### Claim 4 (depends on 1)

The method of claim 1, wherein determining the amount of fetal nucleic acid comprises introducing one or more competitors at known concentrations in an amplification reaction.

### Claim 5 (depends on 4)

The method of claim 4, comprising determining the absolute amount of fetal nucleic acid in the sample.

### Claim 6 (depends on 1)

The method of claim 1, wherein the plurality of loci comprises a locus of SEQ ID NO:154.

### Claim 7 (depends on 1)

The method of claim 1, wherein the plurality of loci comprises a locus of SEQ ID NO:158.

### Claim 8 (depends on 1)

The method of claim 1, wherein the plurality of loci comprises a locus of SEQ ID NO:163.

### Claim 9 (depends on 1)

The method of claim 1, wherein the plurality of loci further comprises loci selected from loci of SEQ ID NOs:1-59.

### Claim 10 (depends on 1)

The method of claim 1, wherein the plurality of loci further comprises loci selected from loci of SEQ ID NO:42 and SEQ ID NO:52.

### Claim 11 (depends on 1)

The method of claim 1, wherein the amount of fetal nucleic acid at 3 or more loci is determined.

### Claim 12 (depends on 11)

The method of claim 11, wherein the amount of fetal nucleic acid at 10 or more loci is determined.

### Claim 13 (depends on 1)

The method of claim 1, further comprising:
i) determining the digestion efficiency of the methylation sensitive restriction enzyme; and
ii) determining the presence or absence of Y-chromosome nucleic acid in the nucleic acid.

### Claim 14 (depends on 13)

The method of claim 13, wherein the amount of Y-chromosome nucleic acid present in the nucleic acid is determined for a male fetus.

### Claim 15 (depends on 14)

The method of claim 14, wherein the amount of fetal nucleic acid is compared to the amount of Y-chromosome nucleic acid.

### Claim 16 (depends on 14)

The method of claim 14, wherein two or more assays are used to determine the total amount of nucleic acid, one or more assays are used to determine the amount of Y-chromosome nucleic acid for a male fetus, and one or more assays are used to determine the digestion efficiency of the methylation sensitive restriction enzyme.

### Claim 17 (depends on 1)

The method of claim 1, wherein determining the amount of fetal nucleic acid in (b) comprises use of a mass spectrometry method.

### Claim 18 (depends on 1)

The method of claim 1, wherein determining the amount of fetal nucleic acid in (b) comprises use of a sequencing method.

### Claim 19 (depends on 18)

The method of claim 18, wherein the sequencing method comprises sequencing by synthesis.
